BIO-TECHNE Corp (TECH) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 3.40%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 3.40% | Share-based compensation / revenue. Period ending 2026-06-30. $41.37M ÷ $1.22B × 100 ≈ 3.40% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | |
| Revenue | 1.22B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 41.37M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 251.89M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $1.22B | $41.37M | $251.89M | (m) | (m) | 3.40% | (m) | (m) |
| 2026-03-31 | (m) | $1.21B | $40.69M | $153.75M | (m) | (m) | 3.36% | (m) | (m) |
| 2025-12-31 | (m) | $1.22B | $41.58M | $116.97M | (m) | (m) | 3.42% | (m) | (m) |
| 2025-09-30 | (m) | $1.22B | $42.33M | $109.93M | (m) | (m) | 3.48% | (m) | (m) |
| 2025-06-30 | (m) | $1.22B | $40.83M | $102.25M | (m) | (m) | 3.35% | (m) | (m) |
| 2025-03-31 | (m) | $1.21B | $43.35M | $171.94M | (m) | (m) | 3.59% | (m) | (m) |
| 2024-12-31 | (m) | $1.20B | $40.09M | $200.23M | (m) | (m) | 3.35% | (m) | (m) |
| 2024-09-30 | (m) | $1.17B | $38.13M | $190.81M | (m) | (m) | 3.25% | (m) | (m) |
| 2024-06-30 | (m) | $1.16B | $38.04M | $206.69M | (m) | (m) | 3.28% | (m) | (m) |
| 2024-03-31 | (m) | $1.15B | $28.89M | $255.39M | $16.93M | (m) | 2.50% | 15.09× | Reported |
| 2023-12-31 | (m) | $1.14B | $30.87M | $268.60M | $14.29M | (m) | 2.70% | 18.80× | Reported |
| 2023-09-30 | (m) | $1.14B | $34.86M | $298.49M | $12.32M | (m) | 3.05% | 24.23× | Reported |
| 2023-06-30 | (m) | $1.14B | $39.23M | $298.94M | $11.21M | (m) | 3.45% | 26.66× | Reported |
| 2023-03-31 | (m) | $1.12B | $49.72M | $284.99M | $10.02M | (m) | 4.43% | 28.45× | Reported |
| 2022-12-31 | (m) | $1.12B | $47.68M | $295.23M | $11.14M | (m) | 4.26% | 26.49× | Reported |
| 2022-09-30 | (m) | $1.12B | $44.91M | $289.69M | $11.69M | (m) | 4.02% | 24.78× | Reported |
| 2022-06-30 | (m) | $1.11B | $42.18M | $296.59M | $11.31M | (m) | 3.82% | 26.23× | Reported |
| 2022-03-31 | (m) | $1.08B | $43.59M | $284.60M | $12.10M | (m) | 4.05% | 23.53× | Reported |
| 2021-12-31 | (m) | $1.03B | $46.16M | $262.78M | $12.26M | (m) | 4.48% | 21.43× | Reported |
| 2021-09-30 | (m) | $984.55M | $47.77M | $251.43M | $12.95M | (m) | 4.85% | 19.42× | Reported |
| 2021-06-30 | (m) | $931.03M | $48.98M | $237.30M | $13.95M | (m) | 5.26% | 17.01× | Reported |
| 2021-03-31 | (m) | $847.84M | $45.19M | $208.02M | $15.28M | (m) | 5.33% | 13.62× | Reported |
| 2020-12-31 | (m) | $798.97M | $42.40M | $187.19M | $17.11M | (m) | 5.31% | 10.94× | Reported |
| 2020-09-30 | (m) | $759.65M | (m) | $173.18M | $18.39M | (m) | (m) | 9.42× | Reported |
| 2020-06-30 | (m) | $738.69M | $32.37M | $157.42M | $19.20M | (m) | 4.38% | 8.20× | Reported |
| 2020-03-31 | (m) | $754.52M | $34.48M | $161.37M | $20.18M | (m) | 4.57% | 8.00× | Reported |
| 2019-12-31 | (m) | $744.70M | $32.35M | $157.67M | $20.80M | (m) | 4.34% | 7.58× | Reported |
| 2019-09-30 | (m) | $734.28M | $29.08M | $154.28M | $21.69M | (m) | 3.96% | 7.11× | Reported |
| 2019-06-30 | (m) | $714.01M | $32.28M | $146.72M | $21.70M | (m) | 4.52% | 6.76× | Reported |
| 2019-03-31 | (m) | (m) | $38.80M | $146.37M | $19.16M | (m) | (m) | 7.64× | Reported |
| 2018-12-31 | (m) | (m) | $37.83M | $145.36M | $16.61M | (m) | (m) | 8.75× | Reported |
| 2018-09-30 | (m) | (m) | $36.01M | $135.91M | $13.18M | (m) | (m) | 10.31× | Reported |
| 2018-06-30 | (m) | (m) | $28.24M | $136.18M | $10.19M | (m) | (m) | 13.37× | Reported |
| 2018-03-31 | (m) | (m) | $17.00M | $133.31M | $9.07M | (m) | (m) | 14.70× | Reported |
| 2017-12-31 | (m) | $599.38M | $16.23M | $123.73M | $8.61M | (m) | 2.71% | 14.36× | Reported |
| 2017-09-30 | (m) | $577.03M | (m) | $117.46M | $8.20M | (m) | (m) | 14.32× | Reported |
| 2017-06-30 | (m) | $563.00M | $14.63M | $120.58M | $7.36M | (m) | 2.60% | 16.38× | Reported |
| 2017-03-31 | (m) | $541.19M | $13.97M | $113.90M | $5.63M | (m) | 2.58% | 20.22× | Reported |
| 2016-12-31 | (m) | $528.12M | $12.32M | $125.13M | $4.08M | (m) | 2.33% | 30.71× | Reported |
| 2016-09-30 | (m) | $517.22M | $10.57M | $145.01M | $2.64M | (m) | 2.04% | 54.93× | Reported |
| 2016-06-30 | (m) | $499.02M | $9.43M | $150.59M | $1.75M | (m) | 1.89% | 86.15× | Reported |
| 2016-03-31 | (m) | $481.92M | $7.91M | $1.51M | $1.70M | (m) | 1.64% | 0.88× | Reported |
| 2015-12-31 | (m) | $465.11M | $6.88M | $-2.59M | $1.65M | (m) | 1.48% | -1.58× | Reported |
| 2015-09-30 | (m) | $456.15M | $6.63M | $-4.04M | $1.68M | (m) | 1.45% | -2.40× | Reported |
| 2015-06-30 | (m) | $452.25M | $5.96M | $147.02K | $1.54M | (m) | 1.32% | 0.10× | Reported |
| 2015-03-31 | (m) | $427.11M | (m) | $148.07M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $408.50M | (m) | $154.41M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $380.57M | (m) | $155.57M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $357.76M | (m) | $159.75M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $344.71M | (m) | $160.72M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $330.15M | (m) | $158.90M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $321.22M | (m) | $160.06M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $310.57M | (m) | $158.47M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $309.78M | (m) | $159.87M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $312.41M | (m) | $162.29M | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $311.99M | (m) | $163.06M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $314.56M | (m) | $166.21M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $313.92M | (m) | $167.59M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $306.57M | (m) | $165.97M | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $299.61M | (m) | $165.64M | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $289.96M | (m) | $163.06M | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | $269.05M | (m) | $156.33M | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | $263.96M | (m) | $150.78M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |